1-20 of 605 results for subject:Patients
Librarians' tools
- Search time
- 0.263 seconds
- Solr query time
- 0.016 seconds
- Search query
- subject:Patients
- We searched for
- subject_t:Patients OR subject_t:"Sick people" OR subject_ses:92375
Type
House
Session
Year
Department
Member
More
Primary member
More
Answering member
Legislative stage
Legislation
Subject
More
Publisher
Find out about the causes and consequences of medicines shortages, and UK Government actions in response to supply disruption affecting human medicines.
Find out about the causes and consequences of medicines shortages, and UK Government actions in response to supply disruption affecting human medicines.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that the rising cost of energy bills do not negatively impact (a) patient safety and (b) services in NHS (i) hospitals and (ii) community services.
To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that the rising cost of energy bills do not negatively impact (a) patient safety and (b) services in NHS (i) hospitals and (ii) community services.
Through the Energy Bill Relief Scheme, the Government will provide a discount on wholesale gas and electricity prices for all non-domestic customers, including public sector organisations in the National Health Service. This will be equivalent to the Energy Price Guarantee in place for households.
NHS England have released a further £1.5 billion to NHS integrated care systems to manage the rising costs of energy and inflation. Local integrated care boards will determine how this funding will be used in hospitals and community services.
To ask the Secretary of State for Health and Social Care, how many patients receiving haemodialysis at home received full reimbursement from the NHS for the resulting energy costs in the financial year (a) 2021-22, (b) 2020-21 and (c) 2019-20.
To ask the Secretary of State for Health and Social Care, how many patients receiving haemodialysis at home received full reimbursement from the NHS for the resulting energy costs in the financial year (a) 2021-22, (b) 2020-21 and (c) 2019-20.
The information requested is not held centrally. Reimbursements are made by the patient’s host provider hospital, with NHS England meeting additional direct utility costs through the payment of the national tariff to the provider. NHS England is promoting awareness of these arrangements with regional commissioning teams, providers of renal services and renal networks to ensure that eligible patients are alerted.
To ask the Secretary of State for Health and Social Care, how many patients receiving haemodialysis at home received partial reimbursement from the NHS for the resulting energy costs in the financial year (a) 2021-22, (b) 2020-21 and (c) 2019-20.
To ask the Secretary of State for Health and Social Care, how many patients receiving haemodialysis at home received partial reimbursement from the NHS for the resulting energy costs in the financial year (a) 2021-22, (b) 2020-21 and (c) 2019-20.
The information requested is not held centrally. Reimbursements are made by the patient’s host provider hospital, with NHS England meeting additional direct utility costs through the payment of the national tariff to the provider. NHS England is promoting awareness of these arrangements with regional commissioning teams, providers of renal services and renal networks to ensure that eligible patients are alerted.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve awareness among patients receiving haemodialysis treatment at home of their right to receive a reimbursement for the energy costs induced by their treatment.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve awareness among patients receiving haemodialysis treatment at home of their right to receive a reimbursement for the energy costs induced by their treatment.
The Department expects providers of home haemodialysis services to inform patients of the National Health Service-funded financial support available to help with increased direct energy costs. For adult home haemodialysis, patients’ additional utility costs are met through the payment of the national tariff to the provider, which reimburses the patient.
NHS England is communicating with all commissioned providers of home dialysis and renal clinical networks to reiterate the existing reimbursement arrangements and ensure that providers alert eligible patients. NHS England will also work with Kidney Care UK and other national charities to promote awareness of reimbursement arrangements.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the fuel claim allowances for NHS patients travelling from rural areas to medical appointments in the context of rising fuel costs.
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the fuel claim allowances for NHS patients travelling from rural areas to medical appointments in the context of rising fuel costs.
No assessment has been made. In England, the level of fuel costs which can be claimed by patients under the Healthcare Travel Costs scheme is determined locally by National Health Service organisations.
To ask the Secretary of State for International Trade, what safeguards are in place to ensure that the (a) price of drugs and (b) NHS including its services and patient data are not compromised in future trade deals.
To ask the Secretary of State for International Trade, what safeguards are in place to ensure that the (a) price of drugs and (b) NHS including its services and patient data are not compromised in future trade deals.
The NHS, the price it pays for drugs and its services are not for sale. The United Kingdom’s published objectives for negotiations with new trade partners make it clear that we will not agree measures that undermine HM Government’s ability to deliver on our manifesto commitments to the NHS.
The United Kingdom’s trade agreements do not undermine the safeguards that we have in place around health and care data. HM Government is clear that health and care data should only ever be used and/or shared where used lawfully, treated with respect, held securely and where the right safeguards are in place. The United Kingdom’s high standards of data protection will be maintained.
Moved by
Baroness Sheehan
10: Clause 1, page 1, line 17, at end insert—
“(d) the importance of prioritising the protection of human rights including citizens’ right to access medicines as part of the right to the highest attainable standard of physical and mental health as stated in the International Covenant on Economic,...
Moved by
Baroness Sheehan
10: Clause 1, page 1, line 17, at end insert—
“(d) the importance of prioritising the protection of human rights including citizens’ right to access medicines as part of the right to the highest attainable standard of physical and mental health as stated in the International Covenant on Economic,...
My Lords, I rise—metaphorically—to move Amendment 10 in my name and those of the noble Baroness, Lady Bennett of Manor Castle, and the noble Lords, Lord Alton of Liverpool and Lord Crisp. It is a pleasure to have their names on an amendment to ensure that affordable medicines for all...
My Lords, I rise—metaphorically—to move Amendment 10 in my name and those of the noble Baroness, Lady Bennett of Manor Castle, and the noble Lords, Lord Alton of Liverpool and Lord Crisp. It is a pleasure to have their names on an amendment to ensure that affordable medicines for all...
My Lords, it is a great pleasure to follow the noble Baroness, Lady Sheehan, and to join the noble Lords, Lord Alton of Liverpool and Lord Crisp, in backing her important amendment. The introduction the noble Baroness provided was powerful and comprehensive, so I will not speak at length. I...
My Lords, it is a great pleasure to follow the noble Baroness, Lady Sheehan, and to join the noble Lords, Lord Alton of Liverpool and Lord Crisp, in backing her important amendment. The introduction the noble Baroness provided was powerful and comprehensive, so I will not speak at length. I...
My Lords, I spoke at some length on this issue in Committee and am delighted that the noble Baroness, Lady Sheehan, has given us the opportunity to explore it again. She has done so with her usual thoroughness and thought. I am also pleased to follow the noble Baroness, Lady...
My Lords, I spoke at some length on this issue in Committee and am delighted that the noble Baroness, Lady Sheehan, has given us the opportunity to explore it again. She has done so with her usual thoroughness and thought. I am also pleased to follow the noble Baroness, Lady...
My Lords, I support this amendment. When we discussed this issue in Committee, I raised the matter of Section 57A of the Patents Act 1977 and the Minister pointed out that compensation needs to be awarded to a patent holder for any loss of profits as a result of the...
My Lords, I support this amendment. When we discussed this issue in Committee, I raised the matter of Section 57A of the Patents Act 1977 and the Minister pointed out that compensation needs to be awarded to a patent holder for any loss of profits as a result of the...
My Lords, I am very pleased to add my name to the amendment in the name of the noble Baroness, Lady Sheehan. I shall be brief and limit myself to one central point, because the arguments have been put so well by noble Lords who have already spoken. At its...
My Lords, I am very pleased to add my name to the amendment in the name of the noble Baroness, Lady Sheehan. I shall be brief and limit myself to one central point, because the arguments have been put so well by noble Lords who have already spoken. At its...
My Lords, the purpose of this amendment, tabled by my noble friend Lady Sheehan, with cross-party support, is to ensure that fair and affordable access to medicines for all must be a consideration when regulations are made with respect to human medicines. This is key for two reasons. The first...
My Lords, the purpose of this amendment, tabled by my noble friend Lady Sheehan, with cross-party support, is to ensure that fair and affordable access to medicines for all must be a consideration when regulations are made with respect to human medicines. This is key for two reasons. The first...
My Lords, I too congratulate the noble Baroness, Lady Sheehan, on another important speech on this key issue and the dogged way she has pursued her arguments and key questions to the Minister. I thank her for sharing her response letter of 7 January to the Minister, which clearly sets...
My Lords, I too congratulate the noble Baroness, Lady Sheehan, on another important speech on this key issue and the dogged way she has pursued her arguments and key questions to the Minister. I thank her for sharing her response letter of 7 January to the Minister, which clearly sets...
My Lords, first, I would like to address the issue of patient and clinician access to affordable medicines in the UK. Patient and clinician access to affordable medicines is at the core of the NHS and this country’s healthcare policy. This Bill will not diminish that. Indeed, a safe and...
My Lords, first, I would like to address the issue of patient and clinician access to affordable medicines in the UK. Patient and clinician access to affordable medicines is at the core of the NHS and this country’s healthcare policy. This Bill will not diminish that. Indeed, a safe and...
My Lords, this has been a stimulating debate and I sincerely thank all noble Lords and noble Baronesses who have taken part. That very much includes the Minister, who responded with her customary courtesy and thoughtfulness.
I thank the noble Baroness, Lady Bennett of Manor Castle. As ever, she brought up...
My Lords, this has been a stimulating debate and I sincerely thank all noble Lords and noble Baronesses who have taken part. That very much includes the Minister, who responded with her customary courtesy and thoughtfulness.
I thank the noble Baroness, Lady Bennett of Manor Castle. As ever, she brought up...
Moved by
Baroness Penn
11: Clause 1, page 1, line 17, at end insert—
“(3A) Where regulations under subsection (1) may have an impact on the safety of human medicines, the appropriate authority may make the regulations only if the authority considers that the benefits of doing so outweigh the risks.”
Member’s explanatory statement
This...
Moved by
Baroness Penn
11: Clause 1, page 1, line 17, at end insert—
“(3A) Where regulations under subsection (1) may have an impact on the safety of human medicines, the appropriate authority may make the regulations only if the authority considers that the benefits of doing so outweigh the risks.”
Member’s explanatory statement
This...
Moved by
Lord Hunt of Kings Heath
13: Clause 2, page 2, line 32, at end insert “, or
(o) the use of tissues or cells (within the meanings given by regulation 5(1) of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (S.I. 2007/1523)) in relation to human medicines.”
Member’s explanatory...
Moved by
Lord Hunt of Kings Heath
13: Clause 2, page 2, line 32, at end insert “, or
(o) the use of tissues or cells (within the meanings given by regulation 5(1) of the Human Tissue (Quality and Safety for Human Application) Regulations 2007 (S.I. 2007/1523)) in relation to human medicines.”
Member’s explanatory...
My Lords, I am delighted to move my amendment, which follows constructive and very helpful discussions with the Government. I am particularly grateful to the noble Lords, Lord Bethell and Lord Ahmad, the noble Baroness, Lady Penn, and their officials for their help, and to my fellow sponsors, the noble...
My Lords, I am delighted to move my amendment, which follows constructive and very helpful discussions with the Government. I am particularly grateful to the noble Lords, Lord Bethell and Lord Ahmad, the noble Baroness, Lady Penn, and their officials for their help, and to my fellow sponsors, the noble...